Efficacy and safety of belumosudil as compared with best available therapy for the treatment of cGVHD in the United States.
- DOI
- 10.1182/bloodadvances.2025015832
- Published
- 2026 Feb 10
- Container
- Blood advances
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1182/bloodadvances.2025015832,
title = {Efficacy and safety of belumosudil as compared with best available therapy for the treatment of cGVHD in the United States.},
author = {Hall K and Lazaryan A and van der Laan M and Lee C and Logan AC and Gruber S and Kabadi S and Khan I and Nicholls C and Rota L and Nikai E and Ponomareva E and Koumas A and Waller EK},
year = {2026},
journal = {Blood advances},
doi = {10.1182/bloodadvances.2025015832},
url = {https://doi.org/10.1182/bloodadvances.2025015832}
}RIS
TY - JOUR TI - Efficacy and safety of belumosudil as compared with best available therapy for the treatment of cGVHD in the United States. AU - Hall K AU - Lazaryan A AU - van der Laan M AU - Lee C AU - Logan AC AU - Gruber S AU - Kabadi S AU - Khan I AU - Nicholls C AU - Rota L AU - Nikai E AU - Ponomareva E AU - Koumas A AU - Waller EK PY - 2026 JO - Blood advances DO - 10.1182/bloodadvances.2025015832 UR - https://doi.org/10.1182/bloodadvances.2025015832 ER -
APA
K, H., A, L., M, V. D. L., C, L., AC, L., S, G., S, K., I, K., C, N., L, R., E, N., E, P., A, K., & EK, W. (2026). Efficacy and safety of belumosudil as compared with best available therapy for the treatment of cGVHD in the United States.. Blood advances. https://doi.org/10.1182/bloodadvances.2025015832
Source records
- pubmed · retrieved 2026-09-26T03:58:05.612Z